Literature DB >> 30012381

A methimazole resistant patient with Graves' disease (GD): A case report of mid-term management with herbal decoctions mainly composed of Anemarrhena Bunge.

Jiman Kim1, Tae-Hun Kim2.   

Abstract

Graves' disease (GD) is the most common cause of hyperthyroidism. Anti-thyroid drugs, including methimazole, are the most commonly selected treatment option for this condition. But for decades, no additional drug option has been added. Anemarrhena Bunge has been used in many herbal decoctions for patients who had hyperthyroidism-like symptoms, such as sweating, heat intolerance, and anxiety. In this case study, a patient with GD who had once achieved therapeutic goals with methimazole but then re-developed hyperthyroidism was treated with only herbal decoctions, and achieved euthyroidism, normalization of T3, T4 levels for 13 months and maintenance of thyroid stimulating hormone (TSH) levels for 8 months and TSH binding inhibitory immunoglobulins (TBII)-negative status for 13 months (TSH and TBII level before treatment: 0.01 μIU/mL, 10.94 IU/L; TSH level normalization after 14 months from the initiation of the treatment: 0.75 μIU/mL, TBII level normalization after 9 months from the initiation of the treatment: 0.8 IU/L). The patient did not report any adverse effects related to this treatment. A herbal decoction with Anemarrhena Bunge might be effective in patients who are resistant to methimazole treatments, a finding which needs further investigation in future.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anemarrhena bunge; Case report; Graves’ disease; Herbal decoction; TSH binding inhibitory immunoglobulins; Thyroid stimulating hormone

Mesh:

Substances:

Year:  2018        PMID: 30012381     DOI: 10.1016/j.ctim.2018.05.015

Source DB:  PubMed          Journal:  Complement Ther Med        ISSN: 0965-2299            Impact factor:   2.446


  2 in total

1.  Effects of Shuganjianpihuatanxingqi decoction on mild subclinical hypothyroidism: A SPIRIT compliant randomized controlled trial study protocol.

Authors:  Litao Bai; Jing Zhao; Jialiang Gao; Fei Li; Fan Wei; Jun Li; Yao Xiao; Xu Han; Yaoli Wang; Danwei Wang; Fangying Wu; Junping Wei
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

Review 2.  Emerging therapeutic role of Prunella vulgaris in thyroid disease.

Authors:  Wen Zhang; Qimuge Wuhan; Meiri Na; Riba Hu; Qier Mu; Xilinqiqige Bao
Journal:  Chin Herb Med       Date:  2022-05-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.